Effect tetrahydroaminoacridine cognition function behaviour Alzheimer disease OBJECTIVE efficacy tetrahydroaminoacridine THA Alzheimer disease DESIGN double-blind multiple crossover trial treatment periods weeks active drug therapy weeks placebo administration SETTING Referral-based geriatric practice community hospital PATIENTS Thirty-four patients moderate Alzheimer disease Subjects stage disease Reisberg scale psychotropic drugs month consent patients next kin INTERVENTIONS Fifty mg THA daily matched placebo RESULTS initial patients liver toxicity gastrointestinal side effects study study able minimum dose patients significant effect THA cognition functional status behaviour results individual patients subgroup THA-responsive patients CONCLUSION THA important benefits Alzheimer disease appreciable toxic effects 